title: [Cutaneous plasmacytomas following treatment of IgA kappa multiple myeloma].
authors.forename: Xavier
authors.initials: X
authors.lastname: Ortín
authors.forename: Andreu
authors.initials: A
authors.lastname: Llorente
authors.forename: Salomé
authors.initials: S
authors.lastname: Martínez
authors.forename: Aránzazu
authors.initials: A
authors.lastname: Ugarriza
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology*; D007145:Immunoglobulin kappa-Chains / Q000276:immunology*; D008297:Male; D008558:Melphalan / Q000009:adverse effects* / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology*; D010954:Plasmacytoma / Q000139:chemically induced*; D011239:Prednisolone / Q000009:adverse effects* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000139:chemically induced*
chemical_list: D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; D007070:Immunoglobulin A; D007145:Immunoglobulin kappa-Chains; D011239:Prednisolone; D008558:Melphalan